Canopy Growth Corp (TSX:WEED) posted a solid rise in consolidated net receipts for the quarter ended September, with international cannabis billings climbing more than twofold year‑over‑year and the adjusted operating loss narrowing slightly, keeping a positive reading within reach for the fiscal year, the company said.
Receipts by Segment
Consolidated net receipts rose significantly versus the prior‑year quarter, driven by higher cannabis sales; Canadian medical receipts increased on more insured customers and the MTL Cannabis acquisition, while Canadian adult‑use revenue grew with flower volumes tied to MTL and a modest decline in bulk shipments, the release noted. International volumes more than doubled, led by Germany and Poland, though the Storz and Bickel vaporizer line slipped modestly as regional demand softened, the filing indicated.
Margins Slip as Adjusted Operating Loss Narrows
Gross margin fell across the board, with cannabis gross margin down mainly because Veterans Affairs Canada reduced its reimbursement rate, and Storz and Bickel’s margin edged higher, the company explained. Operating, general and administrative expenses rose modestly due to MTL integration and headcount reductions, while the adjusted operating loss remained small and improved slightly year‑over‑year, the statement showed.
Fair Value Charges Widen Net Loss
The net loss widened sharply from the previous year, a result of nearly $‑million fair value charges on Canopy USA assets, which represent the firm’s non‑controlling interest in U.S. THC‑exposed holdings, the release disclosed. Management also flagged a material weakness in internal controls and a restated consolidated financial statement for an earlier period, details that appear in filings with SEDAR+ and the Ontario Securities Commission.
Path to Profitability and International Expansion
The CFO said the company is progressing steadily toward positive financial performance and expects a positive adjusted operating measure before the fiscal year ends, implying modest margin gains or cost savings could close the gap, the statement noted. Internationally, the Smiths Falls facility is the sole Canadian site certified for European GMP manufacturing of softgels, oral liquids and dried flower, while the Kincardine cultivation site, recently recertified, underpins an end‑to‑end flower supply chain for European markets, the filing said. The firm appointed a Germany country manager, entered the UK medical market through Spectrum Therapeutics, and launched new oil, softgel and flower formats in Australia, accelerating its global growth agenda.
Canadian Market Backdrop
Canada’s recreational market remains price‑competitive amid provincial distributor pressure and illicit‑market competition, squeezing licensed producers’ margins, whereas the medical channel relies on public and insurer reimbursement, making the VA rate change especially impactful, the report observed. Peers are increasingly turning to export markets and branded products to offset domestic softness, and recent consolidation—exemplified by the MTL Cannabis acquisition—reshapes the competitive landscape, the article noted.
Brands and What to Watch
The portfolio includes adult‑use brands Tweed and Deep Space, the MTL Cannabis family, Storz and Bickel vaporizers, and medical services under Spectrum Therapeutics, the release said. Investors should monitor progress toward a positive core operating measure, further international product launches, any revision to the Veterans Affairs reimbursement framework, and developments at Canopy USA, the filing concluded.
